P715: MULTICENTER OBSERVATIONAL STUDY OF PONATINIB IN CML PATIENTS IN ARGENTINA. REAL-WORLD EXPERIENCE.

Ítems similars

• Nicotinamide–Ponatinib Analogues as Potent Anti-CML and Anti-AML Compounds
  per: Elizabeth Larocque, et al.
  Publicat: (2020-02-01)
• In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy
  per: María Belén Sanchez, et al.
  Publicat: (2023-09-01)
• Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal
  per: Carolina Pavlovsky, et al.
  Publicat: (2023-04-01)
• S152: COMBINATORY THERAPY OF ASCIMINIB AND PONATINIB WAS EFFECTIVE IN THE TREATMENT OF BLAST PHASE CML CDX MODEL
  per: Nikola Čuřík, et al.
  Publicat: (2023-08-01)
• P663: MULTICENTER, PROSPECTIVE AND RETROSPECTIVE OBSERVATIONAL COHORT STUDY OF PONATINIB IN PATIENTS WITH CML IN ITALY: LONG-TERM FOLLOW-UP RESULTS OF THE OITI TRIAL
  per: Massimo Breccia, et al.
  Publicat: (2023-08-01)